Program
Bortezomib
Also written as “bortezomib”, “VELCADE” and “VELCADE TM (bortezomib) for Injection”.
Its studies are mostly in Multiple Myeloma · Carcinoma, Non-Small-Cell Lung · Lymphoma, Mantle-Cell · Lymphoma, Follicular · Amyloidosis, led by 6 companies.
Drug pageBortezomib: every studyMany companies study it; this page follows only the 62 they lead. All 651 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 285 open or running | phase 4since Oct 15, 2014 | Sep 13, 2005 | Feb 14, 2029phase 3 · NCT04923893 |
| Takedaits history only | 250 open or running | phase 4since Nov 18, 2005 | Oct 28, 2002 | none ahead |
| Oncotherapeuticsits history only | 40 open or running | phase 2since Apr 24, 2006 | Apr 19, 2006 | none ahead |
| AbbVieits history only | 32 open or running | phase 3since Nov 28, 2023 | Aug 19, 2016 | Dec 2027phase 3 · NCT06158841 |
| AstraZeneca | 10 open or running | phase 4since Aug 23, 2023 | Aug 23, 2023 | none ahead |
| Clinical Service, Chinaits history only | 10 open or running | phase 2since Mar 29, 2011 | Mar 29, 2011 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of AstraZeneca only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 23, 2023First study: phase 4 study in HypophosphatasiaFirst studyNCT06015750
TargetBeta
“26S proteasome inhibitor; 26S proteasome inhibitor”ChEMBL 37, by rule
Other programs on the same 38 targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| carfilzomibrule | Amgen | phase 4 | 38 |
Studies
The one study AstraZeneca leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06015750Hypophosphatasia | 4 | Withdrawn | Mar 13, 2030 | 0 |
How it is read
Names in the registry
- “Bortezomib”, 42 entries
- “bortezomib”, 18 entries
- “VELCADE”, 6 entries
- “VELCADE TM (bortezomib) for Injection”, 2 entries
- “VELCADE TM (bortezomib) for Injection, or PS-341”, 2 entries
Conditions, from the studies’ own filings
- Multiple Myeloma, 61 studies
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Lymphoma, Mantle-Cell, 3 studies
- Lymphoma, Follicular, 3 studies
- Amyloidosis, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.